{"id":"W3093030175","doi":"10.1016/j.cllc.2020.09.013","title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Bristol-Myers Squibb Canada; National Institutes of Health; Clovis Oncology; Exelixis; Eli Lilly and Company; AstraZeneca; Shire; F. Hoffmann-La Roche; Takeda Pharmaceuticals U.S.A.; Neos Therapeutics; Foundation for the National Institutes of Health; Spectrum Pharmaceuticals; Novartis; National Cancer Institute; AbbVie; Merck; University of Colorado; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Oncology; Lung; Gastroenterology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002935869,0.0005252517,0.001344386,0.0001529737,0.0001817042,0.00002939426,0.0002528629,0.0001590327,0.000613828],"category_scores_gemma":[0.0002010568,0.000369565,0.000198693,0.0007979174,0.0001378252,0.0001782842,0.0001877069,0.0007375494,0.000005739684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009833346,"about_ca_system_score_gemma":0.001426373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001484327,"about_ca_topic_score_gemma":0.002555526,"domain_scores_codex":[0.9956341,0.0003209796,0.001490255,0.001157335,0.0008210168,0.0005763301],"domain_scores_gemma":[0.9973465,0.0003794191,0.0006283502,0.0005736547,0.0005320462,0.000539988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01727151,0.04433048,0.9134901,0.000503256,0.001190462,0.0001777102,0.01014508,0.0002386775,0.00001413005,0.000002293071,0.005835874,0.006800402],"study_design_scores_gemma":[0.1838577,0.1062275,0.6924773,0.0009244016,0.007132109,6.107192e-7,0.004307491,0.002456891,0.0002176167,0.000001000949,0.001541589,0.0008557735],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873098,0.002235193,0.00002866912,0.0005911804,0.0007892858,0.00805016,0.0006994648,0.00007534114,0.000220943],"genre_scores_gemma":[0.9963714,0.0001273191,0.00007833023,0.000813743,0.000359837,0.001301686,0.000135361,0.00009758574,0.0007147539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2210128,"threshold_uncertainty_score":0.9998756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03232496123790799,"score_gpt":0.4204253364912456,"score_spread":0.3881003752533376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}